Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights
Search jobs Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights Continued to advance our portfolio of anti-TIGIT antibodies: On track for the ARC-7 interim analysis for domvanalimab in 2Q21, and the first patient was dosed with AB308 in combination with zimberelimab Presented promising PFS and OS data for etrumadenant in the ≥3L metastatic colorectal cancer setting at AACR Initiated the randomized portion of our ARC-8 study evaluating AB680, our first-in-class small molecule CD73 inhibitor, in pancreatic cancer followi...
Source: pharmiweb.com